Telix Surpasses US$1 Billion Revenue Forecast as Clinical Trials Advance
Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.
- Q2 revenue rises 21% year-on-year to US$247 million
- Precision Medicine sales up 30% year-on-year
- FDA clears Part 2 of ProstACT Phase 3 trial for TLX591-Tx
- Strategic collaboration with Regeneron nets US$40 million upfront
- Convertible bond refinancing extends debt maturity to 2031
Revenue Growth Driven by Precision Medicine
Telix Pharmaceuticals (ASX:TLX) reported group revenue of US$247 million for Q2 2026, marking a 7% increase quarter-over-quarter and a 21% rise compared to the same period last year. The Precision Medicine segment was the standout performer, delivering US$202 million in sales; up 9% from the previous quarter and 30% year-on-year. This growth was underpinned by robust demand for the PSMA imaging agents Illuccix and Gozellix, with US dose volumes increasing 7% during the quarter, reflecting Telix's fortified market leadership in prostate cancer diagnostics.
FDA Endorses Progression of Key Prostate Cancer Trial
On the clinical front, Telix secured a critical regulatory milestone with the U.S. Food and Drug Administration's alignment on Part 2 of the ProstACT Global Phase 3 study for TLX591-Tx, its lead prostate cancer therapeutic candidate. The FDA confirmed that safety data from Part 1 suffices to proceed with Part 2 in the U.S., including agreement on the clinical trial protocol and statistical analysis plan. While U.S. enrolment awaits the FDA’s review of an Investigational New Drug amendment, patient recruitment continues strongly across multiple international sites including Australia, Canada, and China. This development positions Telix to potentially accelerate pivotal data generation in metastatic castration-resistant prostate cancer, a key market for the company.
Strategic Collaboration and Financial Strengthening
Telix's commercial and R&D momentum was further boosted by a strategic partnership with Regeneron Pharmaceuticals (NASDAQ: REGN), focusing on next-generation radiopharmaceutical therapies initially targeting lung cancer. Telix received a US$40 million non-refundable upfront payment as part of this collaboration, which also supports an updated FY 2026 R&D budget of US$230 million to US$270 million. This increase reflects the company’s commitment to accelerating high-value clinical programs, including label expansions and new therapeutic candidates.
Financially, Telix completed a refinancing of its convertible bonds, issuing US$600 million of new bonds due 2031 and retiring the 2029 bonds. This move extends debt maturities and enhances financial flexibility, underpinning the company’s growth strategy amid ongoing clinical and commercial investments.
Manufacturing Expansion and Board Enhancements
Operationally, Telix is scaling its manufacturing capabilities with the opening of a new facility in North Melbourne, in partnership with the Melbourne Theranostic Innovation Centre, and successful Good Manufacturing Practice production runs at its Brussels site. The installation of ARTMS' QUANTM Irradiation System at TMS Yokohama expands isotope production capacity, supporting Telix’s goal of 50 such installations worldwide by year-end.
The company also strengthened its governance with the appointment of three new Non-Executive Directors, bringing enhanced clinical, commercial, and financial expertise to the Board as Telix navigates its dual-listed status and commercial expansion.
Bottom Line?
Telix’s Q2 results and strategic moves position it well for sustained growth, but upcoming regulatory decisions and trial readouts will be pivotal in defining its trajectory.
Questions in the middle?
- Will FDA approval of the ProstACT Part 2 trial enable accelerated U.S. market access for TLX591-Tx?
- How will the Regeneron collaboration influence Telix’s pipeline diversification and revenue streams long term?
- Can Telix’s expanded manufacturing footprint keep pace with anticipated demand for its radiopharmaceuticals?
